J Orthop Sports Phys Ther. 2022 Jun;52(6):312-344. doi: 10.2519/jospt.2022.11075.
To estimate the benefits and harms of interventions with and without surgery for musculoskeletal (MSK) conditions.
Intervention systematic review with meta-analysis of randomized controlled trials (RCTs).
MEDLINE, EMBASE, CINAHL, Web of Science, and CENTRAL, all up to January 7, 2021.
RCTs (English, German, Danish, Swedish, and Norwegian) of interventions with and without surgery conducted in any setting for any non-fracture MSK condition in adults (mean age: 18+ years) evaluating the outcomes on a continuous (benefits) or count (harms) scale. Outcomes were pain, self-reported physical function, quality of life, serious adverse events (SAEs), and death at 1 year.
Random-effects metaanalyses for MSK conditions where there were data from at least 2 trials.
One hundred RCTs (n = 12 645 patients) across 28 different conditions at 9 body sites were included. For 9 out of 13 conditions with data on pain (exceptions include some spine conditions), 11 out of 11 for function, and 9 out of 9 for quality of life, there were no clinically relevant differences (standardized mean difference of 0.50 or above) between interventions with and without surgery. For 13 out of 16 conditions with data on SAEs and 16 out of 16 for death, there were no differences in harms. Only 6 trials were at low risk of bias.
The low certainty of evidence does not support recommending surgery over nonsurgical alternatives for most MSK conditions with available RCTs. Further high-quality RCTs may change this conclusion. .
评估有手术和无手术干预治疗肌肉骨骼(MSK)疾病的获益和危害。
干预系统评价,对随机对照试验(RCT)进行荟萃分析。
MEDLINE、EMBASE、CINAHL、Web of Science 和 CENTRAL,均截至 2021 年 1 月 7 日。
在任何环境中对成人(平均年龄:18 岁以上)非骨折 MSK 疾病进行的有手术和无手术干预的 RCT(英语、德语、丹麦语、瑞典语和挪威语),对连续(获益)或计数(危害)尺度上的结局进行评估。结局包括疼痛、自我报告的身体功能、生活质量、严重不良事件(SAEs)和 1 年时的死亡。
对至少有 2 项试验提供数据的 MSK 疾病进行随机效应荟萃分析。
共纳入 28 个不同身体部位的 28 项不同疾病的 100 项 RCT(n = 12645 例患者)。对于有疼痛数据的 13 项疾病中的 9 项(除外一些脊柱疾病)、功能数据的 11 项中的 11 项以及生活质量数据的 9 项中的 9 项,手术与非手术干预之间没有临床相关差异(标准化均数差值 0.50 或以上)。对于有 SAEs 数据的 16 项疾病中的 13 项和有死亡数据的 16 项疾病中的 16 项,危害没有差异。只有 6 项试验的偏倚风险较低。
基于现有 RCT,低证据确定性不支持对大多数 MSK 疾病推荐手术优于非手术治疗。进一步的高质量 RCT 可能会改变这一结论。